Growth hormone exposure as a risk factor for the development of subsequent neoplasms of the central nervous system: A report from the childhood cancer survivor study

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 6, 2014, Pages 2030-2037

  Patterson, Briana C ^a   Chen, Yan ^b   Sklar, Charles A ^c   Neglia, Joseph ^d   Yasui, Yutaka ^b   Mertens, Ann ^a   Armstrong, Gregory T ^e   Meadows, Anna ^f   Stovall, Marilyn ^g   Robison, Leslie L ^e   Meacham, Lillian R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^f CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE;

ADOLESCENT; ADULT; AGE; ARTICLE; BRAIN RADIATION; CANCER RISK; CANCER SURVIVOR; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHILDHOOD CANCER; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLIOMA; HORMONAL THERAPY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; PATIENT HISTORY OF RADIOTHERAPY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGE OF ONSET; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; CRANIAL IRRADIATION; FEMALE; GLIOMA; HUMAN GROWTH HORMONE; HUMANS; HYPOPITUITARISM; INFANT; INFANT, NEWBORN; MALE; MENINGIOMA; NEOPLASMS, SECOND PRIMARY; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVORS; YOUNG ADULT;

EID: 84902341049     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-4159     Document Type: Article

References (31)

1. Gurney JG, Kadan-Lottick NS, Packer RJ, et al. Endocrine and cardiovascular late effects among adult survivors of childhood brain tumo rs: Childhood Cancer Survivor Study. Cancer. 2003;97(3): 663-673.
2. Mulder RL, Kremer LC, van Santen HM, et al. Prevalence and risk factors of radiation-induced growth hormone deficiency in childhood cancer survivors: a systematic review. Cancer Treat Rev. 2009; 35(7):616-632.
3. Darzy KH, Pezzoli SS, Thorner MO, Shalet SM. Cranial irradiation and growth hormone neurosecretory dysfunction: a critical appraisal. J Clin Endocrinol Metab. 2007;92(5):1666-1672.
4. Darzy KH, Shalet SM. Pathophysiology of radiation-induced growth hormone deficiency: efficacy and safety ofGHreplacement. Growth Horm IGF Res. 2006;16(suppl A):S30-S40.
5. Woodmansee WW, Zimmermann AG, Child CJ, et al. Incidence of second neoplasm in childhood cancer survivors treated with GH: an analysis of GeNeSIS and HypoCCS. Eur J Endocrinol. 2013;168(4): 565-573.
6. Jenkins PJ, Mukherjee A, Shalet SM. Does growth hormone cause cancer? Clin Endocrinol (Oxf). 2006;64(2):115-121.
7. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8(12):915-928.
8. Packer RJ, Boyett JM, Janss AJ, et al. Grow th hormone replacement therapy in children with medulloblastoma: use and effect on tumor control. J Clin Oncol. 2001;19(2):480-487.
9. Sklar CA, Mertens AC, Mitby P, et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrino l Metab. 2002;87(7):3136-3141.
10. Ergun-Longmire B Mertens AC Mitby P et al Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor J Clin Endocrinol Met ab. 2006 91 9 3494-3498.
11. Darendeliler F, Karagiannis G, Wilton P, et al. Recurrence of brain tumours in patients treated with growth hormone: analysis of KIGS (Pfizer International Growth Da tabase). Acta Paediatr. 2006; 95(10):1284-1290.
12. Mackenzie S, Craven T, Gattamaneni HR, Swindell R, Shalet SM, Brabant G. Long-term safety of growth hormone replacement after CNSi rradiation. J Clin Endocrinol Metab. 2011;96(9):2756-2761.
13. Jostel A, Mukherjee A, Hulse PA, Shalet SM. Adult growth hormone replacement therapy and neuroimaging surveillance in brain tumour survivors. Clin Endocrinol (Oxf). 2005;62(6):698-705.
14. Robison LL, Mertens AC, Boice JD, et al. Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multiinst itutional collaborative project. Med Pediatr Oncol. 2002;38(4): 229-239.
15. Robison LL, Armstrong GT, Boice JD, et al. The Childhood Cancer Survivor Study: a National Cancer Institute-suppo rted resource for outcome and intervention research. J Clin Oncol. 2009;27(14): 2308-2318.
16. LeisenringWM,Mertens AC, Armstrong GT, et al. Pediatric cancer survivorship research: experience of the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27(14):2319-2327.
17. Neglia JP, Robison LL, Stovall M, et al. New primary neoplasms of the central nervous system in survivors of ch ildhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2006;98(21):1528-1537.
18. Strodtbeck K, Sloan A, Rogers L, et al. Risk of subsequent cancer following a primary CNS tumor. J Neurooncol. 2013;112(2):285-295.
19. Friend KE, Radinsky R, McCutcheon IE. Growth hormone receptor expression and function in meningiomas: effect of a specific receptor antago nist. J Neurosurg. 1999;91(1):93-99.
20. Kurihara M, Tokunaga Y, Tsutsumi K, et al. Characterization of insulin-like growth factor I and epidermal growth factor receptors in meningioma. J Neurosurg. 1989;71(4):538-544.
21. McCutcheon IE, Flyvbjerg A, Hill H, et al. Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J Neurosurg. 2001;94(3):487-492.
22. Tsutsumi K, Kitagawa N,NiwaM,HimenoA, Taniyama K, Shibata S. Effect of suramin on 125I-insulin-like growth factor-I binding to human meningiomas and on pr oliferation of meningioma cells. J Neurosurg. 1994;80(3):502-509.
23. Schrell UM, Gauer S, Kiesewetter F, et al. Inhibition of proliferation of human cerebral meningioma cells by suramin: effects on cell growth, cell cycle phases, extracellular growth factors, and PDGF-BB autocrine growth loop. J Neurosurg. 1995;82(4):600-607.
24. Friend KE, Khandwala HM, Flyvbjerg A, Hill H, Li J, McCutcheon IE. Growth hormone and insulin-like growth factor-I: effects on the growth of glioma cell lines. Growth Horm IGF Res. 2001;11(2): 84-91.
25. Shimizu K, Adachi K, Teramoto A. Growth hormone enhances natural killer cell activity against glioma. J Nippon Med Sch. 2005; 72(6):335-340.
26. Michaud DS, Gallo V, Schlehofer B, et al. Reproductive factors and exogenous hormone use in relation to risk of glioma and meningioma in a large European cohort study. Cancer Epidemiol Biomarkers Prev. 2010;19(10):2562-2569.
27. Korhonen K, Raitanen J, Isola J, Haapasalo H, Salminen T, Auvinen A. Exogenous sex hormone use and risk of meningioma: a populatio n-based case-control study in Finland. Cancer Causes Control. 2010;21(12):2149-2156.
28. Benson VS, Pirie K, Green J, et al. Hormone replacement therapy and incidence of central nervous system t umours in the Million Women Study. Int J Cancer. 2010;127(7):1692-1698.
29. Sareddy GR, Nair BC, Gonugunta VK, et al. Therapeutic significance of estrogen receptor-agonists in gliomas. Mol Cancer Ther. 2012;11(5):1174-1182.
30. Ramaswamy R, Ashton K, Lea R, et al. Study of effectiveness of mifepristone for glioma cell line growth suppression. Br J Neurosurg. 2012;26(3):336-339.
31. OeffingerKC,MertensAC,HudsonMM,et al. Health care of young adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Ann Fam Med. 2004;2(1):61-70.